Aurinia Pharmaceuticals Aktie [WKN DE: A1W7D4 / ISIN: CA05156V1022]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Aurinia Pharmaceuticals Inc

09.05.23		Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference (Businesswire)
04.05.23		Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results (Businesswire)
02.05.23		ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR” ALL Company Director Nominees at 2023 Annual General Meeting (Businesswire)
02.05.23		Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin) (Businesswire)
28.04.23		Glass Lewis Recommends Aurinia Shareholders Vote "FOR” ALL Company Director Nominees at 2023 Annual Meeting (Businesswire)
25.04.23		Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys (Businesswire)
24.04.23		Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023 (Businesswire)
11.04.23		Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office (Businesswire)
05.04.23		Aurinia Pharma Reports Promising Topline Data From AURORA Renal Biopsy Sub-Study (RTTNews)
05.04.23		Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial (Businesswire)
03.04.23		Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
06.03.23		Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.02.23		Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates (Businesswire)
24.02.23		Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference (Businesswire)
07.02.23		Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023 (Businesswire)
06.02.23		Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
25.01.23		Aurinia Announces PTAB Has Terminated Inter Partes Review (Businesswire)
24.01.23		Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office (Businesswire)
06.01.23		Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results (Businesswire)
04.01.23		Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference (Businesswire)
03.01.23		Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
03.01.23		Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals (Businesswire)
05.12.22		Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
30.11.22		Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis (Businesswire)
03.11.22		Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results (Businesswire)
28.10.22		Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022 (Businesswire)
27.10.22		Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022 (Businesswire)
03.10.22		Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
20.09.22		Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022 (Businesswire)
19.09.22		Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis (Businesswire)
24.08.22		Pre-market Movers: LGO, NERV, TMDX, BBBY, FTCH… (RTTNews)
04.08.22		Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results (Businesswire)
01.08.22		Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
26.07.22		Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review (Businesswire)
25.07.22		Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022 (Businesswire)
22.07.22		Aurinia Pharma Gets Positive CHMP Opinion For LUPKYNIS For Active Lupus Nephritis Treatment (RTTNews)
22.07.22		Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe (Businesswire)
14.07.22		Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance (Businesswire)
10.06.22		AUPH FINAL DEADLINE ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 14 Deadline in Securities Class Act... (PR Newswire)
06.06.22		Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
03.06.22		Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations (Businesswire)
31.05.22		ROSEN, A LEADING AND RANKED FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
25.05.22		AUPH INVESTOR NEWS: TOP RANKED ROSEN LAW FIRM Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
20.05.22		Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress (Businesswire)
16.05.22		Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress (Businesswire)
15.05.22		ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
10.05.22		Aurinia Reports First Quarter 2022 Financial and Operational Results (Businesswire)
09.05.22		ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
06.05.22		Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022 (Businesswire)
02.05.22		Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022 (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

NVIDIA & Co.: Bernstein sieht diese drei KI-Aktien als Top-Chancen für 2025

ATX-Titel Lenzing-Aktie: So viel Verlust hätte eine Investition in Lenzing von vor einem Jahr bedeutet

KTM: Auszahlung offener Gehälter und Löhne ist angelaufen - KTM-Mutter Pierer Mobility-Aktie höher

Auric Minerals-Aktie: Kurssturz wegen neuem Vertrag?

OMV-Aktie gibt nach: OMV Produktion im 4. Quartal 2024 gesunken

NEL ASA-Aktie nach heftigen Kursverlusten mit Gewinnen: Produktionsstopp und Stellenstreichungen im Fokus

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	17.01.2025 00:36
Kaufwert:	EUR
	Hinzufügen Speichern